$9676 | SAVE $1,319 | Single User
$19351 | SAVE $2,639 | Site License
$29027 | SAVE $3,958 | Enterprise License

PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025
[Report Updated: 01-11-2016]

Published by Global Data: 01 Nov 2016 | 43189 | In Stock
Related Topics: Vaccine

Introduction

PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025

Summary

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

Today, available vaccines include the older egg-based, adjuvanted and non- adjuvanted inactivated vaccines, along with live-attenuated vaccines and newer, cell culture-based seasonal influenza vaccines. Within these four vaccine classes, continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus. The anticipated launch of quadrivalent, cell culture-based VLP vaccines will have the potential to revolutionize the approaches used to protect against seasonal influenza infections. GlobalData expects the global seasonal influenza vaccines market - which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) - to grow moderately during the next decade at a CAGR of 3.3%, reaching total sales of .3 billion by 2025.

Highlights

Key Questions Answered

- Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the seasonal influenza vaccine marketplace.

- What will be the effect of recent and upcoming changes in national immunization schedules?

- How will the upcoming first-in-class Virus-Like Particle (VLP) vaccine be received in the different markets?

- What research and development (R&D) strategies will companies leverage to compete in the future seasonal influenza vaccine marketplace?

- Which patient population(s) are most likely to be targeted by seasonal influenza vaccines?

Key Findings

- GlobalData has calculated that the global seasonal influenza vaccine market generated about .1 billion in sales in 2015. This global market is expected to grow modestly at a Compound Annual Growth Rate (CAGR) of 3.3%, reaching sales of .3 billion by 2025. The majority of this growth will occur in the 5EU, driven by the uptake of egg-based, quadrivalent vaccines. Further growth is anticipated due to the launch of cell-culture. quadrivalent vaccines in the 7MM. The seasonal influenza vaccines market in the 5EU is expected to grow at a CAGR of 5.5%, reaching sales of billion by 2025. GlobalData estimates sales in the US to grow moderately at a CAGR of 3.5% during the next 10 years, reaching .6 billion by 2025, while Japan will experience marginal growth, with a CAGR of 0.3%.

- KOLs interviewed by GlobalData repeatedly identified the effectiveness of seasonal influenza vaccines as the number one unmet need. They argued that the influenza virus rapid antigenic drift coupled to a time-consuming egg-based vaccine manufacturing approach are barriers to increasing vaccine efficacy and duration.

- GlobalData anticipates that opportunities will center on the improvement of vaccine long-term efficacy whilst addressing the cost effectiveness concerns voiced by various governmental institutions.

Scope

- Overview of seasonal influenza, including epidemiology, etiology, pathophysiology, as well current routine seasonal influenza vaccine recommendations of all 7MM covered.

- Top-line seasonal influenza vaccine market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the seasonal influenza vaccine market.

- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.

- Analysis of the current and future market competition in the global seasonal influenza vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global seasonal influenza vaccine market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seasonal influenza vaccine market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
for PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025 [Report Updated: 01-11-2016]

  • 1 Table of Contents

    1 Table of Contents 10

    1.1 List of Tables 17

    1.2 List of Figures 24

    2 Introduction 26

    2.1 Catalyst 26

    2.2 Related Reports 27

    2.3 Upcoming Related Reports 27

    3 Disease Overview 28

    3.1 Etiology and Pathophysiology 28

    3.1.1 Etiology 28

    3.1.2 Pathophysiology 33

    3.1.3 Symptoms and Prognosis 34

    4 Epidemiology 36

    4.1 Disease Background 36

    4.2 Risk Factors and Comorbidities 38

    4.3 Global Trends 38

    4.3.1 Historical Perspective of Vaccination Coverage 39

    4.3.2 Laboratory Confirmed Influenza Cases 42

    4.3.3 Hospitalization Due to Influenza 42

    4.3.4 Influenza Averted Cases 43

    4.4 Forecast Methodology 43

    4.4.1 Sources Used Tables 44

    4.4.2 Forecast Assumptions and Methods 48

    4.4.3 Sources Not Used 62

    4.5 Epidemiological Forecast for Seasonal Influenza (2015-2025) 63

    4.5.1 Seasonal Influenza Vaccination 63

    4.5.2 Seasonal Influenza Vaccination Rates 69

    4.5.3 Diagnosed Outpatient Influenza-Like Illness Incident Cases 72

    4.5.4 Lab Confirmed Incident Cases of Seasonal Influenza 79

    4.5.5 Influenza-Related Hospitalized Incident Cases 85

    4.5.6 Cases Averted by Seasonal Influenza Vaccinations 91

    4.6 Discussion 95

    4.6.1 Epidemiological Forecast Insight 95

    4.6.2 Limitations of Analysis 96

    4.6.3 Strengths of Analysis 97

    5 Disease Management 98

    5.1 Seasonal Influenza Immunization Policy 98

    5.1.1 Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines 99

    5.2 US 101

    5.2.1 Influenza Immunization Recommendations and Policies 102

    5.2.2 Clinical Practice 105

    5.3 France 107

    5.3.1 Influenza Immunization Recommendations and Policies 108

    5.3.2 Clinical Practice 110

    5.4 Germany 111

    5.4.1 Influenza Immunization Recommendations and Policies 113

    5.4.2 Clinical Practice 115

    5.5 Italy 117

    5.5.1 Influenza Immunization Recommendations and Policies 119

    5.5.2 Clinical Practice 121

    5.6 Spain 123

    5.6.1 Influenza Immunization Recommendations and Policies 124

    5.6.2 Clinical Practice 126

    5.7 UK 127

    5.7.1 Influenza Immunization Recommendations and Policies 129

    5.7.2 Clinical Practice 131

    5.8 Japan 133

    5.8.1 Influenza Immunization Recommendations and Policies 134

    5.8.2 Clinical Practice 135

    6 Competitive Assessment 138

    6.1 Overview 138

    6.2 Product Profiles - Major Brands, Inactivated Vaccines 140

    6.2.1 Fluzone Quadrivalent 140

    6.2.2 Fluzone High-Dose 146

    6.2.3 Fluzone Intradermal 153

    6.2.4 Vaxigrip 161

    6.2.5 Fluarix Tetra 167

    6.2.6 Fluvirin 174

    6.2.7 Afluria 179

    6.2.8 Agrippal 185

    6.3 Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted) 189

    6.3.1 Fluad 189

    6.4 Product Profiles - Major Brands, Live-Attenuated Vaccines 196

    6.4.1 FluMist Quadrivalent 196

    6.5 Product Profiles - Major Brands, Cell Cultured Vaccines 204

    6.5.1 Flublok 204

    6.5.2 Flucelvax 211

    6.6 Other Seasonal Influenza Vaccines 218

    6.6.1 Influvac 218

    6.6.2 Minor Brands 220

    7 Unmet Needs and Opportunity Analysis 221

    7.1 Overview 221

    7.2 Higher Level of Public Awareness and Positive Perception of Influenza Vaccines 225

    7.2.1 Unmet Need 225

    7.2.2 Gap Analysis 226

    7.2.3 Opportunity 229

    7.3 Immunization Policies Targeting Children and Adolescents 230

    7.3.1 Unmet Need 230

    7.3.2 Gap Analysis 231

    7.3.3 Opportunity 231

    7.4 Enhanced Vaccine Efficacy in High-Risk Groups 233

    7.4.1 Unmet Need 233

    7.4.2 Gap Analysis 234

    7.4.3 Opportunity 236

    7.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies 237

    7.5.1 Unmet Need 237

    7.5.2 Gap Analysis 238

    7.5.3 Opportunity 239

    7.6 Improving the Cost-Effectiveness of Influenza Vaccines 240

    7.6.1 Unmet Need 240

    7.6.2 Gap Analysis 241

    7.6.3 Opportunity 242

    7.7 Vaccines with Broader Influenza Strain Coverage 243

    7.7.1 Unmet Need 243

    7.7.2 Gap Analysis 244

    7.7.3 Opportunity 245

    7.8 Improved Vaccine Safety Profile 246

    7.8.1 Unmet Need 246

    7.8.2 Gap Analysis 247

    7.8.3 Opportunity 248

    8 Pipeline Assessment 249

    8.1 Overview 249

    8.2 Promising Vaccines in Clinical Development 250

    8.2.1 Seasonal Influenza VLP Vaccine 255

    8.2.2 VN-100 264

    8.2.3 Quadrivalent Seasonal Influenza VLP Vaccine 272

    8.3 Promising Vaccines in Early-Stage Development 280

    8.3.1 FLU-v 281

    8.3.2 M-001 282

    8.3.3 TAK-850 283

    8.3.4 VAX-2012Q 283

    8.4 Other Vaccines in Development Outside the 7MM 284

    9 Current and Future Players 285

    9.1 Overview 285

    9.2 Trends in Corporate Strategy 289

    9.3 Company Profiles - Major Players 292

    9.3.1 Sanofi 292

    9.3.2 CSL Limited (Seqirus) 294

    9.3.3 GlaxoSmithKline 296

    9.3.4 AstraZeneca (MedImmune) 297

    9.3.5 Protein Sciences Corporation 300

    9.3.6 Mitsubishi Tanabe Pharma 302

    9.3.7 Novavax 303

    9.4 Other Companies 305

    9.4.1 Mylan 305

    9.4.2 Daiichi Sankyo 306

    10 Market Outlook 307

    10.1 Global Markets 307

    10.1.1 Forecast 307

    10.1.2 Drivers and Barriers - Global Issues 313

    10.2 US 314

    10.2.1 Forecast 314

    10.2.2 Key Events 321

    10.2.3 Drivers and Barriers 322

    10.3 France 323

    10.3.1 Forecast 323

    10.3.2 Key Events 327

    10.3.3 Drivers and Barriers 327

    10.4 Germany 328

    10.4.1 Forecast 328

    10.4.2 Key Events 332

    10.4.3 Drivers and Barriers 332

    10.5 Italy 333

    10.5.1 Forecast 333

    10.5.2 Key Events 337

    10.5.3 Drivers and Barriers 338

    10.6 Spain 339

    10.6.1 Forecast 339

    10.6.2 Key Events 343

    10.6.3 Drivers and Barriers 343

    10.7 United Kingdom 344

    10.7.1 Forecast 344

    10.7.2 Key Events 348

    10.7.3 Drivers and Barriers 349

    10.8 Japan 349

    10.8.1 Forecast 349

    10.8.2 Key Events 354

    10.8.3 Drivers and Barriers 355

    11 Appendix 356

    11.1 Bibliography 356

    11.2 Abbreviations 394

    11.3 Methodology 398

    11.4 Forecasting Methodology 398

    11.4.1 Vaccine Coverage 398

    11.4.2 Vaccines Included 399

    11.4.3 Key Launch Dates 399

    11.4.4 Influenza Vaccine Tender System Assumptions 400

    11.4.5 General Pricing Assumptions 401

    11.4.6 Individual Vaccine Assumptions 402

    11.4.7 Pricing of Pipeline Agents 410

    11.5 Primary Research - KOLs Interviewed for this Report 411

    11.6 Primary Research - Prescriber Survey 414

    11.7 About the Authors 415

    11.7.1 Analyst 415

    11.7.2 Therapy Area Director 415

    11.7.3 Epidemiologists 416

    11.7.4 Director of Epidemiology 417

    11.7.5 Global Director of Therapy Analysis and Epidemiology 417

    11.8 About GlobalData 418

    11.9 Disclaimer 418

List Of Tables
in PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025 [Report Updated: 01-11-2016]

1.1 List of Tables

Table 1: Notable Influenza Pandemics 33

Table 2: Influenza Symptoms 35

Table 3: Risk Factors and Comorbidities for Seasonal Influenza 38

Table 4: 7MM, Historical Perspective of Seasonal Influenza Vaccination Coverage 41

Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Total Population Vaccination Rates of Seasonal Influenza 44

Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Outpatient Seasonal ILI 45

Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Laboratory Confirmed Incident Cases of Seasonal Influenza 46

Table 8: 7MM, Sources of Epidemiological Data Used to Forecast Seasonal Influenza-Related Hospitalized Incident Cases 47

Table 9: 7MM, Sources of Epidemiological Data Used to Forecast Averted Cases of Seasonal Influenza 48

Table 10: 7MM, Sources Not Used in Epidemiological Analysis of Seasonal Influenza 62

Table 11: 7MM, People Receiving Seasonal Influenza Vaccination, All Ages, Both Sexes, N, Selected Years 2015-2025 64

Table 12: 7MM, Age-Specific Distribution of People Receiving Seasonal Influenza Vaccination, Both Sexes, N (Row %), 2015 65

Table 13: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N (Row %), 2015 67

Table 14: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, Selected Years 2015-2025 69

Table 15: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015 71

Table 16: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 73

Table 17: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N (Row %), 2015 75

Table 18: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N (Row %), 2015 77

Table 19: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015-2025 80

Table 20: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N (Row %), 2015 82

Table 21: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N (Row %), 2015 84

Table 22: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 86

Table 23: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N (Row %), 2015 88

Table 24: 7MM, Influenza Related Hospitalized Incident Cases, All Ages, N (Row %), 2015 90

Table 25: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015-2025 92

Table 26: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N (Row %), 2015 94

Table 27: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016 99

Table 28: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016 101

Table 29: Country Profile - US 102

Table 30: Country Profile - France 108

Table 31: Country Profile - Germany 113

Table 32: Country Profile - Italy 118

Table 33: Country Profile - Spain 124

Table 34: Country Profile - UK 129

Table 35: Country Profile -Japan 134

Table 36: Leading Seasonal Influenza Vaccines, 2016 139

Table 37: Product Profile - Fluzone Quadrivalent 141

Table 38: Immunogenicity Profile of Fluzone Quadrivalent 142

Table 39: Local and Systemic AEs of Fluzone Quadrivalent 143

Table 40: Fluzone Quadrivalent SWOT Analysis, 2016 144

Table 41: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015-2025 146

Table 42: Product Profile - Fluzone High-Dose 147

Table 43: Immunogenicity of Fluzone High-Dose Compared with Fluzone 149

Table 44: Local and Systemic AEs of Fluzone High-Dose 150

Table 45: Fluzone High-Dose SWOT Analysis, 2016 151

Table 46: Global Sales Forecast ($m) for Fluzone High-Dose, 2015-2025 153

Table 47: Product Profile - Fluzone Intradermal 155

Table 48: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent 157

Table 49: Local andsystemic AEs of Fluzone Intradermal Quadrivalent 158

Table 50: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016 159

Table 51: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015-2025 161

Table 52: Product Profile - Vaxigrip 163

Table 53: Cumulative Incidence of Influenza Infection in Children 164

Table 54: Local and Systemic AEs of Vaxigrip 165

Table 55: Vaxigrip SWOT Analysis, 2016 165

Table 56: Global Sales Forecast ($m) for Vaxigrip, 2015-2025 167

Table 57: Product Profile - Fluarix Tetra 169

Table 58: Immunogenicity Profile of Fluarix Tetra 170

Table 59: Local and Systemic AEs of Fluarix Tetra 171

Table 60: Fluarix Tetra SWOT Analysis, 2016 172

Table 61: Global Sales Forecast ($m) for Fluarix Tetra, 2015-2025 174

Table 62: Product Profile - Fluvirin 175

Table 63: Immunogenicity of Fluvirin in Adults 176

Table 64: Local and Systemic AEs of Fluvirin 177

Table 65: Fluvirin SWOT Analysis, 2016 178

Table 66: Global Sales Forecast ($m) for Fluvirin, 2015-2025 179

Table 67: Product Profile - Afluria 180

Table 68: Immunogenicity of Afluria in Adults 181

Table 69: Local and Systemic AEs of Afluria 182

Table 70: Afluria SWOT Analysis, 2016 183

Table 71: Global Sales Forecast ($m) for Afluria, 2015-2025 184

Table 72: Product Profile - Agrippal 186

Table 73: Immunogenicity of Agrippal 187

Table 74: Local and Systemic AEs of Agrippal 187

Table 75: Agrippal SWOT Analysis, 2016 188

Table 76: Global Sales Forecast ($m) for Agrippal, 2015-2025 189

Table 77: Product Profile - Fluad 191

Table 78: Immunogenicity Comparison of Fluad Versus Agriflu 192

Table 79: Local and Systemic AEs of Fluad 193

Table 80: Fluad SWOT Analysis, 2016 194

Table 81: Global Sales Forecast ($m) for Fluad, 2015-2025 196

Table 82: Product Profile - FluMist Quadrivalent 198

Table 83: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent 200

Table 84: AEs of FluMist Quadrivalent 201

Table 85: FluMist Quadrivalent SWOT Analysis, 2016 201

Table 86: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015-2025 203

Table 87: Product Profile - Flublok 205

Table 88: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose 207

Table 89: Local and Systemic AEs of Flublok 208

Table 90: Flublok SWOT Analysis, 2016 209

Table 91: Global Sales Forecast ($m) for Flublok, 2015-2025 211

Table 92: Product Profile - Flucelvax 213

Table 93: Immunogenicity of Flucelvax 214

Table 94: Local and Systemic AEs of Flucelvax 215

Table 95:Flucelvax SWOT Analysis, 2016 216

Table 96: Global Sales Forecast ($m) for Flucelvax, 2015-2025 218

Table 97: Summary of Other Marketed Seasonal Influenza Vaccines, 2016 220

Table 98: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016 224

Table 99: Seasonal Influenza Vaccines - Late-Stage Pipeline, 2016 251

Table 100: Quadrivalent Versions of Marketed Vaccines 254

Table 101: Product Profile - Seasonal Influenza VLP Vaccine 257

Table 102: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 262

Table 103: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015-2025 264

Table 104: Product Profile - VN-100 266

Table 105: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine 267

Table 106: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine 268

Table 107: VN-100 SWOT Analysis, 2016 271

Table 108: Global Sales Forecast ($m) for VN-100, 2015-2025 272

Table 109: Product Profile - Quadrivalent Seasonal Influenza VLP Vaccine 274

Table 110: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 278

Table 111: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015-2025 280

Table 112: Promising Vaccines in Early-Stage Development, 2016 281

Table 113: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016 284

Table 114: Key Companies in the Seasonal Influenza Vaccines Market, 2016 288

Table 115: Sanofi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 293

Table 116: CSL Limited’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 295

Table 117: GSK’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 297

Table 118: AstraZeneca’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 299

Table 119: Protein Sciences Corporation’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 301

Table 120: Mitsubishi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 303

Table 121: Novavax’s Seasonal Influenza Vaccine Portfolio Assessment, 2016 305

Table 122: Global (7MM) Sales Forecasts ($m) for Seasonal Influenza Vaccines, 2015-2025 310

Table 123: Seasonal Influenza Vaccines Market - Drivers and Barriers, 7MM, 2015-2025 313

Table 124: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the US, 2015-2025 319

Table 125: Key Events Impacting Sales for Seasonal Influenza in the US, 2015‒2025 321

Table 126: US Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 322

Table 127: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 -2025 325

Table 128: Key Events Impacting Sales for Seasonal Influenza in France, 2015‒2025 327

Table 129: France Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 327

Table 130: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 -2025 330

Table 131: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015‒2025 332

Table 132: Germany Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 332

Table 133: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015-2025 335

Table 134: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015‒2025 337

Table 135: Italy Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 338

Table 136: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 -2025 341

Table 137: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015‒2025 343

Table 138: Spain Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 343

Table 139: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015-2025 346

Table 140: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015‒2025 348

Table 141: UK Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 349

Table 142: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Japan, 2015-2025 352

Table 143: Key Events Impacting Sales for Seasonal Influenza in Japan 2015‒2025 354

Table 144: Japan Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 355

Table 145: Key Launch Dates 400

Table 146: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 414

List Of Figures, Charts and Diagrams
in PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025 [Report Updated: 01-11-2016]

1.2 List of Figures

Figure 1: Influenza Virus Structure 30

Figure 2: 7MM, Cases with Seasonal Influenza Vaccination, All Ages, Both Sexes, N, 2015-2025 64

Figure 3: 7MM, Age-Specific Cases with Seasonal Influenza Vaccination, Both Sexes, N, 2015 66

Figure 4: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N, 2015 68

Figure 5: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, 2015-2025 70

Figure 6: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015 71

Figure 7: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 74

Figure 8: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N, 2015 76

Figure 9: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N, 2015 78

Figure 10: 7MM, Age-Standardized Diagnosed Outpatient ILI Incidence, All Ages, Cases per 100,000 Population, 2015 79

Figure 11: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015-2025 81

Figure 12: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N, 2015 83

Figure 13: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N, 2015 85

Figure 14: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 87

Figure 15: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N, 2015 89

Figure 16: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, N, 2015 91

Figure 17: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015-2025 93

Figure 18: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N, 2015 95

Figure 19: Seasonal Influenza Vaccines - Phase II/Phase III Pipeline, 2016 251

Figure 20: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015-2025 252

Figure 21: Company Portfolio Gap Analysis in Seasonal Influenza Vaccines, 2015-2025 289

Figure 22: Global (7MM) Sales for Seasonal Influenza Vaccines by Country, 2015 and 2025 312

Figure 23: Sales of Seasonal Influenza Vaccines by Class in the US, 2015 and 2025 320

Figure 24: Sales of Seasonal Influenza Vaccines by Class in France, 2015 and 2025 326

Figure 25: Sales of Seasonal Influenza Vaccines by Class in Germany, 2015 and 2025 331

Figure 26: Sales of Seasonal Influenza Vaccines by Class in Italy, 2015 and 2025 336

Figure 27: Sales of Seasonal Influenza Vaccines by Class in Spain, 2015 and 2025 342

Figure 28: Sales of Seasonal Influenza Vaccines by Class in the UK, 2015 and 2025 347

Figure 29: Sales of Seasonal Influenza Vaccines by Class in Japan, 2015 and 2025 353

Additional Details

Publisher

Global Data

Publisher Information

Reference

43189 | GDHC130PIDR

Number of Pages

419

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023SummaryRenal cel...
21 Apr 2016 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024SummaryPsoriasis (PsO) is a...
13 Apr 2016 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024SummaryBipolar disor...
01 Mar 2016 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024...
01 Jan 2016 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024SummaryDry Eye Syn...
05 Nov 2015 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024SummaryAlthough the...
03 Nov 2015 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023SummaryThe Multiple ...
01 Nov 2015 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024SummaryIn t...
01 Oct 2015 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024SummaryMultiple Sc...
10 Sep 2015 by Global Data USD $9,676 (normally
USD $10,995)
More Info
SAVE 12% today! PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024SummaryAllergic Rhi...
01 Sep 2015 by Global Data USD $9,676 (normally
USD $10,995)
More Info

This report is published by Global Data

Download Free Report Summary PDF

PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025 [Report Updated: 01-11-2016] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...